Downgrading Merck to Underperform: The Beat Was Purchase Timing and a Tax Rate, 2027 Is Another Investment Year, and the Stock Has Run Past Fair Value

Results vs. Consensus

Merck reported before the open on Thursday, October 29, with the call at 9:00 a.m. ET. On the headline lines this was the largest beat of our five quarters of coverage. On the lines underneath, it was the most heavily adjusted.

Q3 2026 Scorecard

Year-over-Year Comparison (Q3'26 vs. Q3'25)

Sequential Comparison (Q3'26 vs. Q2'26)

Revenue. Reported growth of 5%, 4% excluding currency, flatters the underlying run-rate in one direction and the comparison flatters it in the other. Remove this year's $550M of timing and revenue grew about 1.5%. The year-ago quarter carried its own $250M Keytruda wholesaler benefit, so adjusting both sides puts underlying growth near 3%, roughly 2% excluding currency. That is a respectable number for a company losing Bridion and Januvia at the rates shown above. It is not the 5% in the headline, and it is not what a 19% EPS beat suggests.

Margins. Gross margin is the one line that improved on the trend we flagged in August. After two quarters of decline and a guide cut to about 81%, the 81.4% print and an unchanged full-year assumption say the erosion has paused. The cost lines are the problem. Interest expense on the debt raised for Cidara and Terns rose to $546M from $327M, and non-GAAP other expense more than tripled to $420M. Operating expenses rose at more than twice the rate of underlying revenue.

EPS. The number that best describes this quarter is non-GAAP pre-tax income excluding business-development charges: $7,314M against $7,750M a year ago, down 6% on reported revenue growth of 5%. A company growing its top line at low single digits underlying while growing operating expenses at low double digits and absorbing a higher interest bill will report shrinking pre-tax income. This quarter that was hidden by a timing benefit above the line and a tax benefit below it.

Segment Performance

Geographic Split

The U.S. now carries the story in both directions. U.S. base Keytruda fell 7%, an acceleration of the 3% decline we first flagged in August. U.S. QLEX of $693M more than covered it, taking the U.S. franchise to $5,213M, up 6.7%. Adjust both years for the purchase timing management quantified, $200M this quarter and $250M a year ago, and the U.S. franchise grew about 8%. That is better underlying demand than the reported line suggests. Internationally the IV base was flat and QLEX added $136M, so the international franchise grew about 4%.

Oncology

Keytruda franchise: 47.6% of revenue, carried by the subcutaneous switch

The franchise delivered $8,601M, up 6% nominal and ex-FX, on earlier-stage use in triple-negative breast, cervical, head and neck and bladder cancer and higher metastatic demand in urothelial cancer. The intravenous product fell to $7,771M, its third consecutive sequential decline from $7,906M in Q1. The franchise's share of total revenue fell to 47.6% from 50.4% in Q2, though that reflects the Gardasil and timing-inflated denominator more than any change in concentration.

"As expected, the timing of US customer purchases last year created a headwind to growth, but this was largely offset by an increase in channel inventory, which we expect to unwind in the fourth quarter." — Caroline Litchfield, Chief Financial Officer

Assessment: The comparison was supposed to be hard this quarter because of the $250M year-ago wholesaler benefit. Management filled most of the hole with $200M of channel inventory that comes back out in the fourth quarter. The franchise did not grow through the lap so much as borrow from the next quarter to cover it. The underlying demand picture is fine. The fourth quarter will look weaker than the run-rate for the same reason.

Keytruda QLEX: $830M, ahead of the Street

QLEX rose 79% sequentially to $830M, 9.7% of the global franchise and 13.3% of the U.S. franchise, against a Street figure near $649M. Japan and China approvals extend the launch to two high-volume markets where management expects high subcutaneous use. Management reaffirmed its goal of 30% to 40% U.S. adoption by the end of 2027.

Assessment: The best number in the release. At this pace the end-2027 target looks reachable, and the jump from 7.9% to 13.3% of the U.S. franchise in a single quarter is faster than our August model assumed. The caveat we raised last quarter still stands: the company has not described how conversion reaches patients on intravenous combination regimens. A new caveat now sits beside it, the patent dispute covered in Key Topics.

Welireg, Lynparza, Lenvima

Welireg grew 56% to $307M on use in previously treated patients and the adjuvant renal cell carcinoma launch, and the Welireg plus Lenvima combination was approved for previously treated advanced RCC during the quarter. Lynparza alliance revenue fell 7% to $352M on U.S. pricing and China demand. Lenvima rose 11% to $287M.

Assessment: Welireg has recovered fully from the LITESPARK-012 failure in Q1 and is now the fastest-growing oncology product outside the Keytruda family. It is still a $1.2B annualized product against a $34B franchise, which is the scale problem every non-Keytruda oncology line faces.

Vaccines

Gardasil rose 14% to $1,995M, with the U.S. up 18% on what management called "a significant CDC purchase and price" and international up 6%. The $300M vaccines timing benefit is predominantly Gardasil, with $50M reversing in the fourth quarter and $250M in 2027. Strip it out and Gardasil was roughly $1.7B, below both the year-ago $1,749M and the Street's $1.76B. Capvaxive rose 8% to $263M on international launches, but U.S. sales fell 13% on lower adult pneumococcal vaccination rates. Vaxneuvance fell 14%. Enflonsia reached $187M on seasonal demand and an inventory build.

"For vaccines, we are watching broader market trends given increased hesitancy and reduced utilization." — Caroline Litchfield, Chief Financial Officer

Assessment: The +14% is the least informative number in the report. Underneath it, Gardasil ex-timing declined, the combined pneumococcal franchise fell about 3% to $458M from $470M, and management named vaccine hesitancy as a 2027 risk for the first time in our coverage. We had moved the Gardasil bear point to contained in August. It goes back to emerging, now broadened to cover vaccine utilization across the portfolio.

Cardiometabolic, Respiratory and Specialty

Winrevair rose 93% to $694M. Of that, $50M is channel inventory that reverses in the fourth quarter, so the clean figure is about $644M, still up about 79%. The HYPERION label update was approved, supporting earlier use. New U.S. patients who received a prescription were "nearly 1,600," down from more than 1,800 in Q2. Ohtuvayre fell to $184M from $204M sequentially as the specialty-pharmacy unwind management flagged in August played through, smaller than feared. LIPFENDRA logged more than 11,000 prescriptions from over 6,500 prescribers in its first full quarter. Bridion collapsed 67% to $144M as multiple generics entered, and Januvia fell 51%.

Assessment: Winrevair remains the cleanest launch in the portfolio, but the new-patient count fell about 12% sequentially and nobody asked about it. LIPFENDRA's script numbers are encouraging, yet management declined to give revenue and confirmed that coupons and samples will weigh on near-term sales, with broad commercial coverage in 2027 and Medicare in 2028. The Bridion decline is steeper than a single quarter of generic entry usually produces, and it is the largest single contributor to the more than $2B of 2027 LOE headwinds.

Animal Health

Animal Health delivered $1,676M, up 4% nominal and 3% ex-FX. Livestock grew 2% on poultry demand and Companion Animal grew 6% on new launches, with Bravecto flat ex-FX at $264M. U.S. Animal Health fell 2%.

Assessment: Slower than the 5% ex-FX of Q2 and the 7% of a year ago. Still ballast, still free of patent and policy risk, but the ballast is growing more slowly than it was when we initiated.

Key Topics & Management Commentary

Overall Management Tone: Confident and pipeline-led, as in August, but noticeably more willing to manage expectations on the near term. Management volunteered the timing breakdown, repeated the 2027 investment-year framing in prepared remarks and again in the first answer, and told the Street directly that most 2027 estimates were too high. Where it was least forthcoming was on the numbers that frame the current quarter: the intravenous Keytruda decline, the tax contribution to the guide and the implied fourth quarter went unaddressed.

1. The Beat Was Built on Timing and Tax

The CFO's own walk-through supplies the decomposition. Third-quarter sales "benefited by approximately $550 million from favorable purchase timing in the US." The tax rate "was 10.9 percent, reflecting a benefit from certain discrete items." Each of those is disclosed, neither is recurring, and together they account for about $0.23 of a $0.40 EPS beat and about 71% of a $775M revenue beat.

"We had a benefit in the third quarter of $550 million as a result of the timing of purchases. $200 million of that relates to KEYTRUDA, which we will expect to unwind in full in the fourth quarter. $50 million relates to WINREVAIR, which we expect to unwind in the fourth quarter. A further $300 million relates to our vaccines business, which is predominantly GARDASIL." — Caroline Litchfield, Chief Financial Officer

The same quarter a year ago also had help: a $250M Keytruda wholesaler benefit and $200M of Koselugo upfront and milestone revenue. Comparisons in either direction need adjustment. What does not need adjustment is the trend in operating profit, which is down year over year on any of these bases.

Assessment: Management deserves credit for quantifying every piece, which it did not have to do. But a reader who stops at the headline will think Merck's underlying business accelerated this quarter. It did not. Underlying revenue grew at low single digits and underlying pre-tax income fell.

2. Base Keytruda Fell 5%, and 7% in the U.S.

In August we called the 1% global decline in intravenous Keytruda an inflection point. This quarter the decline steepened to 5% globally and 7% in the U.S. Some of that is the year-ago $250M wholesaler benefit, which sat in the intravenous base. Even after removing that year-ago benefit, U.S. intravenous sales fell about 2%, and that is before removing any of this quarter's channel build. The franchise still grows because QLEX is substituting for the intravenous product at an accelerating rate.

"For KEYTRUDA, moderating growth reflects the success we have had in reaching the eligible patients as we now approach peak revenues for certain approved indications. Additionally, we expect the German market to be impacted by policy dynamics." — Caroline Litchfield, Chief Financial Officer

Assessment: "Approach peak revenues for certain approved indications" is new language and it is more direct than August's "peak penetration." It now comes with two new headwinds, German policy and ex-U.S. pricing. The franchise is in its plateau phase two years ahead of the loss of exclusivity. The franchise holds up only as long as QLEX keeps converting.

3. QLEX Is Converting Faster Than Planned

QLEX was 1.6% of the global franchise in Q1, 5.5% in Q2 and 9.7% in Q3. In the U.S. it moved from 7.9% to 13.3% in a quarter. The president of the oncology business tied the trajectory to the permanent J-code that took effect April 1 and reaffirmed the U.S. adoption goal.

"Since we received the permanent J-Code on April 1, it's really been a very positive trajectory and we feel good about the objective of getting to that 30 percent to 40 percent adoption in the United States by the end of 2027." — Jannie Oosthuizen, President, Oncology and MSD International

Assessment: On track, and the strongest evidence for the cliff-bridge pillar in our coverage window. At roughly five points of U.S. share a quarter, 30% arrives around the middle of 2027. The open question remains the same one: the easy patients convert first, and the rate may slow once conversion reaches patients on intravenous combination regimens.

4. The Cliff Bridge Now Has a Patent Question

A Dutch court has issued an injunction in a patent dispute over the hyaluronidase enzyme in the subcutaneous formulation. For now Merck will not supply QLEX in Italy, Denmark, the Netherlands, France, Belgium and Ireland. Management characterized the affected markets as low-volume and the ruling as a holding injunction pending a hearing, and emphasized confidence in its U.S. position. The patent holder is also pursuing an infringement case in the United States.

"The injunction you're seeing in Europe is just an injunction until the hearing is held. It doesn't speak to the merits of our belief. We continue to feel very good that we have a position both in the US and in Europe." — Robert Davis, Chairman and Chief Executive Officer

Assessment: The European volumes at stake are small, and we take management at its word that they are immaterial to the subcutaneous total. The importance lies elsewhere. QLEX is the mechanism by which Merck carries roughly a third of its U.S. Keytruda franchise past the December 2028 intravenous loss of exclusivity. A patent challenge to the formulation is therefore a challenge to the bridge itself, and the U.S. case is the one that matters. Management offered confidence but no timeline and no detail on the merits.

5. 2027 Is Another Investment Year

Management first described 2027 at an investor conference in September, and the call repeated and extended it. Revenue: modest growth, with new launches and Animal Health offset by more than $2B of generic and LOE headwinds in Bridion, the Januvia family and Adempas, moderating Keytruda, German policy, ex-U.S. pricing and the $250M Gardasil purchase unwind. Costs: underlying operating expenses up at a mid-to-high single-digit rate, slightly higher interest expense and a slightly higher tax rate. Offset: gross margin rises as a royalty on Keytruda rolls off.

"For 2027, we see it as another year of investment as we invest behind our expansive pipeline and our new product launches to drive long-term growth." — Caroline Litchfield, Chief Financial Officer

Our rough arithmetic on that framework: low-single-digit revenue growth plus a royalty-driven margin gain produces gross-profit growth of roughly the same size as a mid-to-high single-digit increase on a base of about $27.5B of underlying operating expenses. Add higher interest and tax and 2027 underlying EPS lands roughly flat on 2026's ~$8.85, with a plausible range of about $8.60 to $9.10.

Assessment: 2025 non-GAAP EPS was $8.98, or $9.18 before $0.20 of business-development charges. 2026 is now guided to about $8.85 on the same basis. 2027 looks roughly flat. That would be three years of flat-to-down earnings before the loss of exclusivity begins, and across them the stock has re-rated from under 10x to almost 17x on roughly the same earnings. The investment may well be the right decision for the 2030s. It is also the reason the next twelve months look harder than the last twelve.

6. The Guide Raise Was Mostly the Tax Rate

The EPS range moved to $2.77–$2.82 from $2.66–$2.76, and now absorbs the new $0.12 SciBrunch charge. Like-for-like, the midpoint rose $0.205. In the same update, the tax-rate guide fell three points to 32–33%. On roughly $10.3B of implied non-GAAP pre-tax income, three points of tax is worth about $0.12 per share. The operating-expense range rose $300M at the midpoint against a $400M SciBrunch charge, so underlying spending guidance edged down by about $100M. Revenue moved up $250M at the midpoint.

Assessment: About 60% of the like-for-like raise is tax. The rest is the revenue raise and slightly lower underlying spending. The guide also embeds roughly $0.15 of foreign-exchange benefit at mid-October rates. None of these are bad sources of earnings. None of them say anything about demand, and none should be capitalized at the stock's current multiple.

7. The Implied Fourth Quarter Is a Down Quarter

Year-to-date non-GAAP EPS is $1.08. The new range implies fourth-quarter EPS of $1.69 to $1.74, about $1.72 at the midpoint, against $2.04 a year ago. That is a decline of about 16%. Revenue of $15.8B to $16.3B against $16,400M implies a 2% decline at the midpoint, of which $300M is the Keytruda, Winrevair and vaccines unwind. Taken literally, "approximately 81%" gross margin for the year against 81.5% year-to-date implies a fourth quarter near 79.5%.

Assessment: Some of this is conservatism. Merck has beaten its implied fourth quarter before, and "approximately" covers a range. But the direction is not in doubt: the timing comes back out, the interest bill stays, and the fourth quarter is the first in which the 2027 cost trajectory starts to show. Implied second-half EPS of about $4.21 compares with $4.62 a year ago.

8. The $70 Billion Opportunity Is Going Up

Asked to update the mid-2030s framing, the chief executive said the number will be raised and named three sources: Terns, which was not in the original figure; the PD-1/VEGF bispecific, for which nothing was included; and intismeran, whose target product profile has improved on the Phase 3 data. He also expects broader sac-TMT indications as new studies start.

"But that said, what we've seen so far gives me great confidence and increased confidence in that $70 billion. And as such, as we've indicated, we expect now to be raising that number, not only because what we're seeing confidence in what we have, but what wasn't included, which is, I think, part of your question." — Robert Davis, Chairman and Chief Executive Officer

Assessment: A genuine positive and the single most important forward statement on the call. It is also a non-risk-adjusted revenue figure for the mid-2030s, it carries no date for the raise, and its biggest new component, PD-1/VEGF, has no Phase 3 data yet. It supports the long-term thesis. It does not change the earnings arithmetic for 2027 or 2028.

9. ESMO Validated Two Platforms

TroFuse-005 reduced the risk of death by 32% and the risk of progression or death by 41% versus chemotherapy in previously treated endometrial cancer, a near seven-month median overall survival gain. The FDA accepted the filing for priority review with a June 15, 2027 action date, and management hopes for earlier approval. INTerpath-001, with Moderna, reduced the risk of recurrence or death by 42% (HR 0.58) for intismeran plus Keytruda versus Keytruda alone in resected stage IIB–IV melanoma, which management called the first Phase 3 validation of a therapeutic cancer vaccine. KEYNOTE-C93 showed a 43% reduction in progression risk for Keytruda monotherapy in dMMR endometrial cancer. Merck plans Phase 3 studies of sac-TMT with MK-2010 in first-line lung cancer in the first half of 2027.

"These results, building on the body of evidence from the Phase 2b study, strengthen our confidence in the curative potential of intismeran." — Dean Li, President of Merck Research Laboratories

Assessment: A strong conference. TroFuse-005 converts a first-mover strategy into a filed product, and INTerpath-001 gives Merck a new modality that pairs with Keytruda in early-stage disease, the setting where the franchise is strongest. Both lengthen the post-2028 story. Neither contributes meaningful revenue before 2028, and intismeran's economics are shared with its partner.

10. The Vaccine Franchise Has a Utilization Problem

The CFO's 2027 list included vaccine hesitancy and reduced utilization, the first time in our coverage that management has cited hesitancy. It frames vaccines as a market-level risk, not only a product-specific one. The evidence is in the quarter: U.S. Capvaxive fell 13% despite share gains because fewer adults were vaccinated, and Gardasil's strength was a purchase-timing event that partly reverses next year.

"From a vaccines perspective, we have seen a benefit of a CDC buy-in 2026 of approximately $250 million that will unwind in 2027." — Caroline Litchfield, Chief Financial Officer

Assessment: Vaccines were roughly $3.6B of revenue in the quarter across Gardasil, the pediatric vaccines, pneumococcal, RotaTeq and Enflonsia. A market-level utilization decline would affect all of them at once, and none of it is under Merck's control. We are re-escalating the Gardasil bear point and widening it to the vaccine portfolio.

11. Launch Scorecard: Strong, With Softer Edges

Winrevair, Welireg, QLEX and Enflonsia all grew strongly. The edges were softer. New Winrevair patients fell about 12% sequentially. Ohtuvayre declined sequentially. LIPFENDRA revenue was withheld. Capvaxive declined in the U.S.

"So in the third quarter, we saw more than 11,000 prescriptions. And this is coming from over 6,500 prescribers." — Brian Foard, President, Specialty Pharma and Infectious Diseases

Assessment: The launch portfolio is still the best part of the near-term story, but four of the seven launches we track showed at least one soft metric this quarter. None of them is a problem yet. Together they are a reminder that "strong contributions from new product launches" in the 2027 framework is an assumption that still has to be earned.

12. Setbacks and Smaller Deals

The ifinatamab deruxtecan filing for previously treated small cell lung cancer, which carried an October 10 action date, was withdrawn after the FDA indicated the Phase 2 data were insufficient for accelerated approval. The Phase 3 trial continues. Business development shifted to licensing: a $400M upfront for SciBrunch's oral KRAS G12D inhibitor, with up to $2.13B in total value. Management reaffirmed about $3B of buybacks this year and kept the door open to further deals, including commercial-stage assets.

Assessment: The I-DXd withdrawal is a regulatory setback, and it got a single sentence on the call. It delays rather than ends the program. The slowdown in deal size since Terns answers one of our August questions in Merck's favor. The open reference to buying commercialized products is a reminder that a larger deal remains possible.

Guidance & Outlook

2027 Framework (qualitative)

The revenue range now represents growth of 3% to 4% on 2025's $65,011M, including about one point of currency benefit. The midpoint moved $250M against a third-quarter revenue beat of $775M, of which $550M was timing. Management passed through the non-timing part of the beat and kept the ceiling unchanged, a pattern consistent with the last three quarters.

Implied Q4 ramp: fourth-quarter revenue of $15.8B to $16.3B, about $16.1B at the midpoint, against $16,400M a year ago, after a $300M timing unwind. Fourth-quarter non-GAAP EPS of about $1.72 against $2.04. Underlying full-year EPS, excluding the Cidara ($3.62), Terns ($2.31) and SciBrunch ($0.12) charges, is about $8.85, up from about $8.64 in August and below 2025's $9.18 on the same basis.

Street at: the CFO said most published 2027 estimates do not yet reflect the September framework. We expect the February guide to reset 2027 consensus lower, not higher.

Guidance style: unchanged. Merck sets achievable ranges, passes through operating beats, and this quarter let a lower tax rate do most of the work in the raise. The revenue ceiling has not moved since May.

Analyst Q&A Highlights

Whether 2027 Is in Consensus, and Whether Earnings Can Grow Through the LOE

The opening question asked two things: whether the September 2027 comments were reflected in estimates, and whether today's elevated research spending effectively pulls the earnings trough forward so that earnings can grow from here through the exclusivity loss. Management answered the first directly and the second with a framework rather than numbers.

Q: "I'm just interested, do you feel that that's now appropriately reflected in consensus estimates?"
— Christopher Schott, JPMorgan

A: "As we look at consensus estimates for 2027, there are a number of different estimates from the different analysts and some have incorporated the messaging that we've given, many have not yet. So hopefully, this will provide clarity as to our expectations for 2027. And as we look at earnings as we move forward, we do expect to see our company have earnings as we move towards the LOE period grow."
— Caroline Litchfield, Chief Financial Officer

Assessment: The clearest negative-revision signal management has given in our coverage. A CFO who says most estimates are wrong is telling the Street which way they are wrong. The longer-term answer, that earnings grow into the LOE period, then dip shallowly, then mirror revenue's return to growth, is the first time management has spoken to the earnings profile and not just to revenue. It is still a shape, not a number.

How Much of the Quarter Was Purchase Timing

A question about Winrevair's one-time benefit prompted the CFO to give the full timing breakdown by product and by the quarter in which each piece reverses. It was the most useful disclosure of the call.

Q: "One of you could quickly just quantify the one-time benefit you saw specifically for WINREVAIR this quarter."
— Vamil Divan, Guggenheim Securities

A: "In terms of the timing benefits that we saw in the quarter, if I may give the full picture inclusive of WINREVAIR so that we have it out there for all. We had a benefit in the third quarter of $550 million as a result of the timing of purchases. ... We expect $50 million to unwind in the fourth quarter and the remaining $250 million to unwind in 2027."
— Caroline Litchfield, Chief Financial Officer

Assessment: Transparent and complete, and it changes how the quarter should be read. The fact that the full breakdown came only in response to a narrow question, rather than in the prepared remarks, is worth noting. The prepared remarks gave the $550M total but not its split.

The Subcutaneous Patent Dispute in Europe and the U.S.

The one question on the formulation litigation asked whether the European injunction was definitive, whether there was a path back to launch, and whether any risk extends to the U.S. Management answered on confidence and on European volumes, and did not address the U.S. case beyond asserting its position.

Q: "Can you just contextualize where we're at in Europe relative to the US? Is this a definitive call? Are there likely paths to moving back towards the launch in these European countries? And is there any risk in the US as we move forward given that the path and the intentions and the litigation that is ongoing?"
— Courtney Breen, Bernstein

A: "So for now, we will not supply in Italy, Denmark, the Netherlands, France, Belgium, and Ireland. These in general are smaller volume markets, so it's immaterial in terms of our overall volume of subcutaneous."
— Jannie Oosthuizen, President, Oncology and MSD International

Assessment: The European answer was specific and credible. The U.S. half of the question, the one that matters for the cliff bridge, got only the chief executive's general statement of confidence. Investors should treat the U.S. case as an open risk with no disclosed timeline.

LIPFENDRA's First Quarter and the Free-Drug Question

A direct request for LIPFENDRA revenue and the share of free-drug prescriptions was declined. The prescription metrics that followed were substantive, and the access timeline was confirmed.

Q: "I'm curious what LIPFENDRA sales were in the quarter and what percent of prescriptions are free drug?"
— Steve Scala, TD Cowen

A: "Now, keep in mind. I think as Rob had mentioned, we have sampling and coupon programs that are out there today that will affect revenue in the short-term. But we're also actively in discussions with payers, and the whole goal there is to get as rapid access as possible. Commercial, we expect, as we had mentioned before, large coverage of the access in the commercial space in the 2027 timeframe. And then for Medicare, it's actually in the 2028 timeframe as well."
— Brian Foard, President, Specialty Pharma and Infectious Diseases

Assessment: Withholding revenue on a launch with 11,000 prescriptions usually means the revenue is small relative to the scripts, which the coupon and sampling comment confirms. The useful information is the access calendar. Broad commercial coverage arrives in 2027 and Medicare in 2028, so LIPFENDRA's meaningful revenue starts in the year the Keytruda exclusivity loss begins.

What Is Not Yet in the $70 Billion

Asked for an updated framing of the mid-2030s opportunity, the chief executive committed to raising it and listed the additions.

Q: "So maybe just double-click on the pushes and pulls that have occurred to influence that and remind us on what wasn't incorporated into that framing and what surprised you to the positive side and what's still underappreciated."
— Asad Haider, Goldman Sachs

A: "And I would just remind you that when we gave that number, we did not have the Terns acquisition included. That is going to be addition to that number. In addition to that, we really put nothing in for the PD-1/VEGF, which now given what you've heard coming out of several different conferences and other meetings."
— Robert Davis, Chairman and Chief Executive Officer

Assessment: The bull case's strongest moment on the call. The additions are concrete and the commitment is explicit. What it lacks is a date, a size, and risk adjustment, and the largest unpriced component, PD-1/VEGF, is the one with the least clinical evidence behind it.

Reading Across From Melanoma to Other Tumors for the Cancer Vaccine

A question asked how intismeran's efficacy broke down by neoantigen count and driver mutation, as a read-through to the upcoming renal cell carcinoma study. Management declined to front-run unpublished subgroup data and cautioned against the read-through.

Q: "And my question is, how does that efficacy break down for patients that had a lower number of neoantigens, and perhaps even more importantly, patients that did not have a major driver mutation like NRAS or BRAF, et cetera? I'm just trying to think through the implications for the upcoming RCC readout."
— Umer Raffat, Evercore ISI

A: "So, I would be a little bit cautious for me to over-interpret any data in, for example, lower TMB in melanoma as a signal for RCC. ... I'm not so sure that parsing the TMB within melanoma will give me any increased or decreased confidence in relationship to RCC."
— Dean Li, President of Merck Research Laboratories

Assessment: A reasonable scientific answer that also signals the limits of the melanoma win. Melanoma is a high-mutation tumor; the platform's value depends on working in lower-mutation settings, and that evidence does not exist yet. INTerpath-001 is a landmark for one indication. Whether it becomes a platform is a 2027 and 2028 question.

Combinations in Immunology and the Business-Development Door

A question on combination strategy for the TL1A antibody drew a cautious scientific answer, and then an unprompted addition from the chief executive on business development that went further than the question required.

Q: "Do you think it is strategically important to have all the complementary mechanisms in-house? Or would you be comfortable partnering with some established market -- marketed products at this point to find the best combination?"
— Mohit Bansal, Wells Fargo

A: "So we actually have a range of internal assets that could be potential combination partners, but we also remain open on the business development front, both in terms of products and development as well as commercialized products."
— Robert Davis, Chairman and Chief Executive Officer

Assessment: The scientific answer conceded that immunology combinations have mostly disappointed. The business answer kept the door open to buying a marketed immunology product. After four acquisitions in three quarters and a slower quarter of licensing, that is the line to remember the next time an announcement interrupts a quiet stretch.

What They're NOT Saying

1. The intravenous Keytruda decline, again. Base Keytruda fell 5% globally and 7% in the U.S. The call never used the word "intravenous" and discussed only the franchise total. The decline appears only in the product table.
2. How much of the guide raise is tax. The three-point tax-rate cut is worth about $0.12 of a $0.205 like-for-like raise. Management presented the EPS raise and the tax change as separate line items and never connected them.
3. The implied fourth quarter. Management told investors which timing benefits reverse in the fourth quarter but did not frame the resulting quarter: EPS of about $1.72 against $2.04, and revenue down about 2%.
4. The size of the 2027 consensus gap. "Many have not yet" incorporated the framework, but management gave no revenue or EPS range for 2027. The February guide will be the first number.
5. The U.S. patent case. The patent holder was never named, the U.S. litigation got no timeline, and the earlier German injunction was not mentioned. For the product that carries the cliff bridge, the disclosure was thin.
6. Winrevair's new-patient slowdown. "Nearly 1,600" new U.S. patients compares with "more than 1,800" in Q2. Management reported the number without a comparison and no one asked.
7. LIPFENDRA revenue. Asked directly, management declined to give it. Script and prescriber counts were offered instead.
8. How QLEX reaches combination-regimen patients. For the second consecutive quarter, the 30% to 40% target was reaffirmed without describing conversion in intravenous combination regimens.
9. The I-DXd withdrawal's commercial impact. One sentence in prepared remarks, no question, no discussion of what the lost accelerated pathway costs in time.

Market Reaction

• Pre-print setup: MRK closed at $140.93 on October 28, up 33.9% year to date against the S&P 500's 13.1%, and up 62.8% over twelve months. It entered the print 5.6% lower over the trailing 30 days and 9.9% below its $156.45 closing high of August 25. The 52-week closing range was $82.49 to $156.45.
• Reaction session (October 29): the stock opened near $148.07, up 5.1%, and traded to $149.26 (+5.9%) in the first half hour. It faded to a $145.78 low in the afternoon and closed at $146.33, up 3.8% or $5.40.
• Relative move: the S&P 500 fell 0.3% on the session, so MRK outperformed by about 4.1 percentage points.
• Volume: 13.4M shares against a 30-day average of 10.4M, or 1.3x.
• Next-day session (October 30): MRK rose another 2.2% to $149.52 while the S&P 500 fell 1.8%. Over the two sessions the stock gained 6.1% against an index decline of 2.1%.
• Since our August note: from $128.00 to $149.52, up 16.8%, while the S&P 500 fell 2.0%.

A headline-led rally into a pullback. The stock had given back about a tenth of its value from the August high, partly after the September conference where management first described 2027 as an investment year. That made the 2027 framing old news by October 29. What was new was a 19% EPS beat, QLEX well ahead of the Street, a raised guide and a chief executive promising a bigger $70B. Buyers acted on those at the open.

The intraday fade is the informative part. The high came within the first half hour, around the time the call reached the timing breakdown and the 2027 discussion. From there the stock gave back about two points into the afternoon. We read that as the market discounting part of the beat once its composition was public, though not much of it.

The second day was about the market, not the company. A 2.2% gain on a session when the index fell 1.8% fits a defensive, dividend-paying large-cap drawing flows in a weak tape, with several price-target increases helping. It also pushed the stock to $149.52, close to where it traded before the September conference and about 16.9x our underlying 2026 estimate.

Street Perspective

Debate: Was the Beat Real?

Bull view: the beat was broad across Keytruda, QLEX, Winrevair, Gardasil and Welireg, the guide went up on both lines, and QLEX alone was well ahead of models. Timing items come and go every quarter, and a 19% EPS beat is not explained away by them.

Bear view: roughly 71% of the revenue beat and more than half of the EPS beat came from purchase timing and a discrete tax rate. Ex-timing, the Keytruda franchise and Winrevair were in line and Gardasil missed. Underlying pre-tax income fell year over year.

Our take: the bears. QLEX is the one genuine upside surprise and it is a substitution, not new demand. The quarter was operationally solid and financially flattered.

Debate: How Far Do 2027 Estimates Have to Fall?

Bull view: 2027 is a deliberate investment year that pulls the earnings trough forward. The royalty roll-off helps margins, the launches keep scaling, and the market will look through a flat year to growth in the 2030s.

Bear view: management has now said twice that 2027 is an investment year and told the Street most models are too high. Revisions tend to lead multiples, and the February guide is likely to be the catalyst.

Our take: the bears for the next twelve months, the bulls for the next ten years. A flat 2027 is a reasonable strategy and a poor setup for a stock at 16.9x.

Debate: Is the Pipeline Now Worth the Multiple?

Bull view: the pipeline has de-risked faster than anyone guided for two consecutive quarters, the $70B is going up, and the average published price target sits near $160. A company that can describe its exclusivity loss as a hill deserves a market-like multiple, and MRK still trades below the market's.

Bear view: the $70B is non-risk-adjusted and dated to the mid-2030s, the newest components have the least data, and the intravenous base is already shrinking two years before the loss of exclusivity. The stock has moved from under 10x to almost 17x on earnings that have not grown, so the whole gain came from the multiple.

Our take: the pipeline is worth more than it was in August, and we raise our estimates accordingly. It is not worth 17% more in under three months. The stock has priced the good news ahead of the evidence, which is the reverse of where it stood when we initiated at Outperform.

August's Commitments and Triggers, Graded

We are stating this plainly because it matters for how the downgrade should be read. None of the three fundamental downgrade triggers we published in August fired. Neither upgrade trigger fired either. The fundamentals moved slightly in Merck's favor on the pipeline and slightly against it on 2027. The price moved 16.8% while the index fell 2.0%. This downgrade is a valuation call.

Model Update Needed

Valuation impact: we keep our multiple range at 14x to 16x underlying 2026 earnings and apply it to the higher base of about $8.85, which moves fair value to $124–142 from $120–138. We considered raising the multiple for INTerpath-001 and the larger $70B, and decided against it. Those gains accrue mostly after 2030, while the 2027 reset pushes flat earnings a year further out, and we judge the two roughly offsetting at the multiple level. At $149.52 the stock trades at 16.9x on the same basis, against 14.5x at our August price of $128.00. Our midpoint of $133 implies about 11% downside, or roughly 9% after the 2.3% yield on the $3.40 annualized dividend. The average published Street target sits near $160, which implies about 18x. We disagree with that number, and that disagreement is the rating.

Thesis Scorecard Post-Earnings

Overall: the thesis is unchanged in its parts and worse in its price. The pipeline pillar is stronger again, and QLEX is converting ahead of plan. Against that, the valuation pillar has broken, the vaccine bear point has re-emerged, and the no-growth bear point now covers two years instead of one. In August the pillars rotated and netted to a Hold at a mid-range price. This quarter they net to roughly the same fundamental view at a price above our range.

Action: Downgrade to Underperform from Hold. We initiated at Outperform at $86.28 on valuation and the twelve-month catalyst path. We moved to Hold in February, and in August we held at $128.00 because the stock sat mid-range on fair value. At $149.52, above the top of a range we have raised again, the same discipline points the other way. We would move back to Hold on a price inside our range, below about $142, without a change in fundamentals. We would also move back on a February 2027 guide showing underlying EPS growth, or on QLEX reaching 20% of the U.S. franchise with the U.S. patent case resolved in Merck's favor. What would make us wrong is a market that keeps paying for de-risking ahead of revenue, as it has all year. The February guide is the test of which effect is larger.